Huang et al. 2022 propose that metformin could be a repositioning medication for the treatment of NAFLD with high levels of ALT, AST, triglyceride (TG), total cholesterol (TC), and IR [182]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.